ASH Big Shot Interview | Professor Jie Jin : IL1RAP-TCE Antibody Effectively Eliminates Leukemia Stem Cells in AML

ASH Big Shot Interview | Professor Jie Jin : IL1RAP-TCE Antibody Effectively Eliminates Leukemia Stem Cells in AML

2024.01.05
From December 9 to 12, 2023, the 65th American Society of Hematology (ASH) Annual Meeting was grandly held in San Diego, USA, in a hybrid format combining online and offline sessions. As one of the largest and most comprehensive international academic conferences in the field of hematology, experts and scholars from around the world gathered to explore the latest frontiers in hematologic diseases, new treatment methods and strategies, and disease management approaches. At this year's ASH Annual Meeting, Professor Jin Jie and her team from the First Affiliated Hospital of Zhejiang University School of Medicine presented an oral report titled "IL1RAP-Specific T Cell Engager (TCE) Antibody Effectively Clears Leukemia Stem Cells (LSC) in Acute Myeloid Leukemia (AML)." "Tumor Watch" had the privilege of interviewing Professor Jin Jie on-site to discuss the research and its related content.
ASCO China Voice | Breaking Survival Records: Avapritinib Combined with Azacitidine Achieves Median Overall Survival of 29.3 Months in Unfit AML!

ASCO China Voice | Breaking Survival Records: Avapritinib Combined with Azacitidine Achieves Median Overall Survival of 29.3 Months in Unfit AML!

2024.01.03
From June 2nd to 6th, 2023, the American Society of Clinical Oncology (ASCO) Annual Meeting took place in a grand hybrid format in Chicago. ASCO Annual Meeting stands as one of the world's largest, academically esteemed, and most authoritative international conferences in oncology. Encompassing cutting-edge advancements in all sub-specialties of oncology, the event attracts the attention of global oncology scholars. In the hematology poster discussion session, the AGILE study presented updates on efficacy and safety data (Abstract 7012). The results of this study were previously published in the prestigious journal "The New England Journal of Medicine" in April 2022. Professor Jianxiang Wang from the Hematology Hospital of the Chinese Academy of Medical Sciences, one of the AGILE researchers, provided insights into the latest data.
Year-End Review | Professor Jianxiang Wang: Targeted New Drugs Lead the Wave of Advances in AML Treatment, Immunotherapy Also on the Rise!

Year-End Review | Professor Jianxiang Wang: Targeted New Drugs Lead the Wave of Advances in AML Treatment, Immunotherapy Also on the Rise!

2024.01.03
Acute Myeloid Leukemia (AML) is a malignant clonal disease originating from hematopoietic stem cells. Affected myeloid cells (leukemic cells) undergo uncontrolled proliferation, differentiation disorders, and blocked apoptosis, accumulating in the bone marrow and other hematopoietic tissues. This inhibits normal hematopoietic function and infiltrates organs such as lymph nodes, liver, and spleen, leading to clinical features including anemia, infections, bleeding, and leukemic cell infiltration. As the most common hematologic malignancy, research in the field of AML, both basic and clinical, has never ceased, yielding continuous breakthroughs. So, what significant advancements has the AML field witnessed in the past year? "Oncology Frontier" has invited Professor Jianxiang Wang from the Institute of Hematology, Chinese Academy of Medical Sciences, to meticulously review various developments in the AML domain. The summary is compiled below.